NU651 Unit 6 Minor Stroke DAPT Case Write-Up Example

Course	NU651 AGACNP Introduction to Acute Care Management Clinical I
Unit	Unit 6
Paper type	Focused case write-up
Length	About 1,140 words, 7 pages double-spaced
Format	APA 7 student paper
School	Purdue University Global
Program	MSN
Updated	September 2026

Free sample paper for NU651 Unit 6

Twenty-One Days of Two Antiplatelets: A Focused Case Write-Up Testing Whether a 69-Year-Old With a Minor Stroke Resembles the Trial Patients

[Student Name]

Purdue University Global

NU651: AGACNP Introduction to Acute Care Management Clinical I

Unit 6 Focused Case Write-Up

[Instructor Name]

[Date]

The patient is composite; times, scores and doses are bracketed.

What this part is doingThe case is told only as far as the decision needs, because the write-up defends one choice rather than surveying stroke care.

Case Presentation

Mr. [F.] is a [69]-year-old retired bus driver with hypertension and hyperlipidemia who noticed clumsiness in his right hand and slurred speech at about [19:00] while eating dinner. He went to bed expecting it to pass, and his wife brought him to the emergency department at [09:00] the next morning, [14] hours after onset. His NIH Stroke Scale score was [2]: mild dysarthria and mild weakness of the right hand. CT of the head showed no hemorrhage, and CT angiography showed no large vessel occlusion and no significant carotid stenosis. MRI showed a [9] mm acute infarct in the left internal capsule, consistent with small vessel disease. His ECG showed sinus rhythm. He takes lisinopril and was prescribed atorvastatin but stopped it [a year] ago. He takes no antiplatelet or anticoagulant.

The Decision

Two acute treatments were considered and set aside. Intravenous thrombolysis was not offered because he was well beyond the time window from when he was last known to be well, and his deficits were mild and not disabling. Thrombectomy was not an option without a large vessel occlusion.

The decision this write-up defends is secondary prevention: aspirin [325 mg] and clopidogrel [300 mg] as loading doses today, then daily clopidogrel [75 mg] together with low-dose aspirin [81 mg] through day [21], after which clopidogrel continues on its own. The alternative was aspirin alone, which was standard care before the two trials described below.

Evidence

The CHANCE trial randomized 5,170 patients in China with a minor ischemic stroke (NIH Stroke Scale score of 3 or less) or high-risk transient ischemic attack, within 24 hours of onset, to clopidogrel with aspirin for 21 days followed by clopidogrel alone, or to aspirin alone (Wang et al., 2013). Stroke at 90 days occurred in 8.2 percent with the combination and 11.7 percent with aspirin alone, and moderate or severe bleeding occurred in 0.3 percent of each group.

The POINT trial randomized 4,881 patients at 269 sites in several countries with the same severity limits but within 12 hours of onset, to clopidogrel with aspirin for 90 days or to aspirin alone (Johnston et al., 2018). Major ischemic events occurred in 5.0 percent with the combination and 6.5 percent with aspirin alone, but major bleeding was higher with the combination, 0.9 against 0.4 percent. Most ischemic events occurred in the first week.

A pooled analysis of individual patient data from both trials clarified why the durations differed. The benefit of clopidogrel with aspirin was concentrated in the first 21 days, 5.2 against 7.8 percent, with no significant benefit from day 22 to day 90, while major bleeding continued to be more frequent with the combination (Pan et al., 2019). The benefit arrives early and stops; the bleeding risk does not, which is why 21 days became the working answer. The American Heart Association secondary prevention guideline recommends dual antiplatelet therapy started early for patients with minor stroke or high-risk transient ischemic attack, for 21 to 90 days, followed by a single agent (Kleindorfer et al., 2021).

What this part is doingThe evidence section ends with the finding that set the duration, so the reader sees where 21 days comes from.

Fit: Does He Resemble the Trial Patients?

This is the section that matters most, because a trial result applies to a patient only as far as he resembles the people studied.

Severity: his NIH Stroke Scale score of [2] is within the limit of 3 or less in both trials. Stroke type: a small subcortical infarct is a noncardioembolic ischemic stroke, the type both trials enrolled; he has no atrial fibrillation on his ECG, and telemetry is running. Bleeding risk: he has no history of bleeding, no anticoagulant and no recent surgery, so he would not have been excluded on those grounds.

Timing is where he fits one trial and not the other. At [14] hours from onset, he is inside the 24-hour window of CHANCE and outside the 12-hour window of POINT. The trial that supports him on timing enrolled only patients in China, a population in which reduced-function variants of the CYP2C19 gene, which blunt clopidogrel's effect, are common. That limits how precisely the CHANCE result carries to him, but it would, if anything, underestimate clopidogrel's effect in a patient who processes the drug normally. The pooled analysis found no evidence that the effect varied across trials or prespecified subgroups.

On balance he is close to the patients in both trials, and the one point of difference, timing, is covered by CHANCE and by the guideline, which recommends starting early rather than within a strict window.

What this part is doingThe fit is tested criterion by criterion, and the one mismatch is named and weighed rather than hidden.

Why Not Aspirin Alone, or 90 Days

Two alternatives deserve an answer. Aspirin alone would expose him to fewer bleeding events, but in both trials it also allowed more early strokes, and the first week is when a second stroke is most likely. For a man with a new internal capsule infarct, a second event in the same territory could take away the use of his right hand. The absolute benefit in the pooled analysis, about two to three events avoided per hundred patients in the first 21 days, outweighs the small absolute increase in bleeding over that period.

Ninety days of dual therapy, as in POINT, would add bleeding exposure for more than two months after the period in which the pooled analysis found the benefit. The guideline allows a range from 21 to 90 days; for a patient with a small vessel infarct and no stenosis, the shorter course captures nearly all of the benefit.

Risks and Monitoring

The main risk of the plan is bleeding. He will be asked about black stools, easy bruising and nosebleeds at follow-up, and the second antiplatelet stops on day [21] without waiting for a visit. A proton pump inhibitor is not added routinely, since he has no history of ulcer or gastrointestinal bleeding.

The Rest of Secondary Prevention

Atorvastatin [80 mg] daily restarts today, with a talk about why he stopped it. Blood pressure will be lowered gradually after the first [24 to 48] hours toward a long-term target below [130/80]. An ambulatory heart monitor will be arranged at discharge to look for atrial fibrillation. He will stop driving until he is reviewed at the stroke clinic in [two] weeks.

Conclusion

Twenty-one days of clopidogrel with aspirin is the right choice for Mr. [F.] because his stroke is minor and noncardioembolic, he has no bleeding history, and he presented within the window of the trial whose regimen he will follow. The write-up rests the decision on those facts rather than on the diagnosis alone.

References

Johnston, S. C., Easton, J. D., Farrant, M., Barsan, W., Conwit, R. A., Elm, J. J., Kim, A. S., Lindblad, A. S., & Palesch, Y. Y. (2018). Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. New England Journal of Medicine, 379(3), 215-225. https://doi.org/10.1056/NEJMoa1800410

Kleindorfer, D. O., Towfighi, A., Chaturvedi, S., Cockroft, K. M., Gutierrez, J., Lombardi-Hill, D., Kamel, H., Kernan, W. N., Kittner, S. J., Leira, E. C., Lennon, O., Meschia, J. F., Nguyen, T. N., Pollak, P. M., Santangeli, P., Sharrief, A. Z., Smith, S. C., Jr., Turan, T. N., & Williams, L. S. (2021). 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline from the American Heart Association/American Stroke Association. Stroke, 52(7), e364-e467. https://doi.org/10.1161/STR.0000000000000375

Pan, Y., Elm, J. J., Li, H., Easton, J. D., Wang, Y., Farrant, M., Meng, X., Kim, A. S., Zhao, X., Meurer, W. J., Liu, L., Dietrich, D., Wang, Y., & Johnston, S. C. (2019). Outcomes associated with clopidogrel-aspirin use in minor stroke or transient ischemic attack: A pooled analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trials. JAMA Neurology, 76(12), 1466-1473. https://doi.org/10.1001/jamaneurol.2019.2531

Wang, Y., Wang, Y., Zhao, X., Liu, L., Wang, D., Wang, C., Wang, C., Li, H., Meng, X., Cui, L., Jia, J., Dong, Q., Xu, A., Zeng, J., Li, Y., Wang, Z., Xia, H., & Johnston, S. C. (2013). Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. New England Journal of Medicine, 369(1), 11-19. https://doi.org/10.1056/NEJMoa1215340

Reading the NU 651 Unit 6 instructions

The Unit 6 assignment asks for a focused write-up of one patient from your rotation built around one diagnosis and one management decision. You present the case briefly, state the decision, summarize the evidence behind it, and assess how well the patient matches the populations studied. Most prompts also ask you to address risks, alternatives and monitoring. The focus is depth rather than breadth, so a survey of every aspect of the diagnosis earns less than a close reading of the one choice. Four to five pages with primary trials and a current guideline is typical. Pick the decision that was genuinely debated on the team, since that is where the evidence has the most work to do.

How this NU651 Unit 6 example is built

The example presents the case only as far as the decision needs, from onset time to MRI. It explains in two sentences why acute reperfusion treatments did not apply, then states the regimen with loading doses. The evidence section summarizes each trial with population, window, regimen, outcomes and bleeding, then uses the pooled analysis to explain the duration. A fit section tests severity, stroke type, bleeding risk and timing one at a time and names the mismatch. A section answers the two alternatives, aspirin alone and 90 days. Risks, the rest of secondary prevention and a short conclusion complete it. The conclusion restates the decision in terms of this patient's facts, not the diagnosis alone.

Where the points sit in the NU651 Unit 6 rubric

The Unit 6 rubric generally scores the case presentation, how clearly the decision is framed, how accurately the trials are reported, how well they are applied to this man, and the plan. Case presentation earns full credit when it includes the details the decision depends on, such as time from onset and stroke severity. Evidence is judged on accurate reporting of trial populations and results. Application is weighted heavily; the rubric rewards checking the patient against inclusion criteria rather than assuming the trials apply. The plan counts when it covers monitoring and the remainder of care. Correct APA format for trials and guidelines is expected. Rubrics also reward naming the one criterion where the patient and the trial differ.

NU651 Unit 6 help from the desk

A frequent mistake is quoting trial results without their populations, which makes the fit section impossible. Another is choosing 90 days of dual therapy without addressing bleeding after the benefit ends. Students often miss the difference in time windows between the two trials. Some write a general stroke paper instead of a focused one. Thrombolysis is sometimes dismissed without a reason. The plan may forget statins, blood pressure or rhythm monitoring. And a conclusion that repeats the guideline without linking it to the patient's own facts loses the point of the assignment. Name the trial whose regimen the patient follows, since the loading doses differ between them.

Get an NU651 Unit 6 example written to your instructions

An admitting diagnosis from the NU651 rotation case, whichever decision the section wants examined, the rubric and the evidence level it requires shape the sample. Expect it within 24-48h, free on a first order, arguing one decision about a fictional admission and testing the trials behind it against that patient's own features. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.

More NU651 papers and MSN samples

NU651 Unit 6 questions, answered

How is a focused case write-up different from a full case study?

A full case study covers the whole admission; a focused write-up picks one diagnosis and usually one decision, then examines the evidence for it in depth. The sample spends most of its pages on dual antiplatelet therapy and summarizes the rest of the stroke care briefly. A prompt asking for a broader scope would get a broader sample.

What if the patient does not match any trial well?

Then the gap is named, and the reasoning proceeds from the closest evidence. The sample finds its patient inside one trial's window and outside the other's, and treats that openly rather than hiding it. Guidelines often extend trial findings to similar patients, and a write-up can cite that extension while acknowledging it.

Can the write-up be based on a patient from my rotation?

Many sections expect exactly that, stripped of identifying details, and the student brings the case. An invented patient carries the sample, which exists to show structure and evidence handling. Hours at the site, encounter records and anything the preceptor rates are the student's; the sample neither describes nor replaces them.

Where can I find a free NU651 Unit 6 sample paper?

Every part of the NU651 Unit 6 focused write-up appears here: the case, both trials, the pooled analysis and a criterion-by-criterion fit section. If your write-up centers on another decision, a free sample can be written from your case.

Why 21 days of dual antiplatelet therapy in NU651 Unit 6?

A pooled analysis of CHANCE and POINT found the benefit of clopidogrel with aspirin concentrated in the first 21 days, with no significant benefit afterward while bleeding continued. The guideline allows 21 to 90 days, and the sample chooses the shorter course.